News

Ideas That Generate Results

A rise in geriatric population across the globe is making the countries move to cheaper APIs and formulations. It is estimated that around US$ 40 Billion worth of drugs in the US and US$ 25 Billion worth of drugs in Europe will be going off patent. There will be a series of patent expirations of important prescription drugs in the coming years. Patent expiry of Lipitor by Pfizer, Diovan by Novartis, Plavix by Bristol-Myers Squibb etc. have already pushed Indian generic players to expand in international markets. Subsequently, some of the other global pharma majors such as Teva, GlaxoSmithKline, and Allergen etc. are likely to lose patent exclusivity of several drugs.
 
According to our research report, “Opportunities in Indian API Market”, the patent expiry of blockbuster drugs is of special importance to India. This is because India specializes in the manufacturing of generic drugs of the highest quality as compared to the generic drugs manufactured in other countries. Therefore, the patent cliff is giving significant opportunity to Indian manufacturers to develop generic versions of respective patented drugs. The generic version of drugs will in turn boost the generic drug API in India.  
 
The demand of generic drugs is rising across the world owing to the lower cost and rising awareness. These drugs are cheap and show similar efficacy, so people prefer these over the expensive branded drugs. Rising global demand of generic drugs will give a significant thrust to the Indian API market. India can make gain out of this situation as generic drug APIs manufactured in India can then be used for domestic manufacture of generic drugs and which can then be exported to other regulated foreign markets.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM788.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm